This listing of claims will replace all prior versions, and listings of claims in the application:

Listing of Claims:

1. (Original) An isolated polynucleotide comprising:

a) the nucleotide sequence of SEQ ID NO: 1, or a transcriptionally active fragment thereof;

b) nucleotides 1-2605, 2011-2605, 2011-5342, 3331-3656, 3421-3548 or 3495-3599 of SEQ ID NO: 1; or

c) nucleotides 3331-3656, 3495-3599 or 3421-3548 of SEQ ID NO: 1.

2. (Original) An isolated polynucleotide comprising, nucleotides 3331-3656, 3495-3599 or 3421-3548 of SEQ ID NO: 1 spliced downstream of nucleotides 1-2558 of SEQ ID NO: 1.

3. (Original) An isolated polynucleotide that hybridizes under highly stringent conditions to the complement of the polynucleotide of Claim 1.

4. (Canceled)

5. (Original) An isolated polynucleotide that comprises the complement of the polynucleotide of Claim 1.

6. (Previously Amended) An isolated polynucleotide comprising the polynucleotide of Claim 1 operably associated with a heterologous coding sequence.

7. (Previously Amended) A vector comprising the polynucleotide of Claim 1.

8. (Previously Amended) An expression vector comprising the polynucleotide of Claim 1 operably associated with a heterologous coding sequence.

9. (Previously Amended) A genetically engineered host cell comprising the polynucleotide of Claim 1.

10. (Previously Amended) A genetically engineered host cell comprising the polynucleotide of Claim 2 operably associated with a heterologous coding sequence.

11. (Canceled.)

12. (Original) The polynucleotide of claim 6, wherein the heterologous coding sequence is a reporter gene.

13. (Original) The polynucleotide of claim 12, wherein the reporter gene is *LacZ*.

14.-20. (Canceled.)

21. (Original) An isolated polynucleotide having a sequence identical in sequence to 20 contiguous nucleotides of the sequence as set forth in SEQ ID NO: 1.

22. (Currently added) An isolated polynucleotide comprising a smooth muscle (SM) α-A promoter/enhancer in operable association with a heterologous polynucleotide, wherein the promoter/enhancer comprises sufficient sequence from the first intron of the SM α-A gene to confer smooth muscle cell-specific expression *in vivo*.

23. (Currently added) The isolated polynucleotide of claim 22, wherein the promoter/enhancer is a human SM α-A promoter/enhancer.

24. (Currently added) The isolated polynucleotide of claim 23, wherein the sequence from the first intron comprises SEQ ID NO: 16, SEQ ID NO:19 and SEQ ID NO:20.

25. (Currently added) The isolated polynucleotide of claim 24, wherein the sequence from the first intron comprises the human sequence depicted in Figure 13.

26. (Currently added) The isolated polynucleotide of claim 24, wherein the promoter/enhancer comprises SEQ ID NO:14 and SEQ ID NO:15.

27. (Currently added) The isolated polynucleotide of claim 24, wherein the promoter/enhancer comprises the human sequence depicted in Figure 12.

28. (Currently added) The isolated polynucleotide of claim 22, wherein the heterologous polynucleotide comprises a coding sequence.

29. (Currently added) The isolated polynucleotide of claim 28, wherein the coding sequence encodes a reporter gene product.

30. (Currently added) The isolated polynucleotide of claim 22, wherein the promoter/enhancer is a rat SM α-A promoter/enhancer.

31. (Currently added) The isolated polynucleotide of claim 30, wherein the sequence from the first intron comprises the rat AP1-like, Int CArG and GATA elements depicted in Figure 10B.

32. (Currently added) The isolated polynucleotide of claim 31, wherein the sequence from the first intron comprises the rat sequence depicted in Figure 13.

33. (Currently added) The isolated polynucleotide of claim 31, wherein the promoter/enhancer comprises the rat CArG B and CArG A elements depicted in Figure 10A.

34. (Currently added)The isolated polynucleotide of claim 33, wherein the promoter/enhancer comprises the rat sequence depicted in Figure 12.

35. (Currently added) A vector comprising the polynucleotide of claim 22.

36. (Currently added) A genetically-engineered host cell comprising a polynucleotide comprising a SM α-A promoter/enhancer in operable association with a heterologous polynucleotide, wherein the promoter/enhancer comprises sufficient sequence from the first intron of the SM α-A gene to confer smooth muscle cell-specific expression *in vivo*.

37. (Currently added) The host cell of claim 36, wherein the promoter/enhancer is a human SM α-A promoter/enhancer.

38. (Currently added) The host cell of claim 36, wherein the sequence from the first intron comprises SEQ ID NO: 16, SEQ ID NO:19 and SEQ ID NO:20.

39. (Currently added) The host cell of claim 36, wherein the sequence from the first intron comprises the human sequence depicted in Figure 13.

Cancel

40. (Currently added) The host cell of claim 36, wherein the promoter/enhancer is a rat SM α-A promoter/enhancer.

41. (Currently added) The host cell of claim 36, wherein the sequence from the first intron comprises the rat AP1-like, Int CArG and GATA elements depicted in Figure 10B.

42. (Currently added) The host cell of claim 36, wherein the sequence from the first intron comprises the rat sequence depicted in Figure 13.